Skip to main content
. 2006 Jul 17;149(1):100–109. doi: 10.1038/sj.bjp.0706832

Table 4.

Effect of adenylate cyclase activation and protein kinase A pathway inhibition on relaxations to PACAP 38, VIP and rolipram

  n pD2 Emax (%)
PACAP 38
  
  
  
Control
 6
 6.9±0.1
 86.4±4.3
Forskolin (30 nM)
 6
 7.3±0.1*
 85.2±4.1
Control
 6
 7.0±0.1
 90.1±7.0
Rp-8-CPT-cAMPS (100 μM)
 6
 —
 39.3±8.3*
 
  
  
  
VIP
  
  
  
Control
 7
 7.2±0.1
 68.6±6.3
Forskolin (30 nM)
 7
 7.4±0.2
 91.4±3.2*
Control
 6
 7.5±0.2
 94.9±3.0
Rp-8-CPT-cAMPS (100 μM)
 6
 —
 61.8±8.1*
 
  
  
  
Rolipram
  
  
  
Control
 7
 8.1±0.1
 65.5±2.2
Rp-8-CPT-cAMPS (100 μM) 7 — 32.3±4.1*

Results are expressed as mean±s.e.m. of n experiments.

*

Significantly (P<0.05) different compared (paired t-test) to the control value. Emax is the maximal relaxation, expressed as a percentage of the PhE-induced contraction, obtained for each drug. pD2=−log EC50, where EC50 is the concentration of agonist producing 50% of the Emax.